

Dr. John Goudreau received his medical degree and doctorate in neuropharmacology through the DO-PhD program at Michigan State University College of Osteopathic Medicine (MSUCOM) in 1995. He completed his residency in neurology at the Mayo Clinic in 2000, where he was given the Mayo Brothers Distinguished Fellowship Award. After residency, Dr. Goudreau completed a movement disorders fellowship at the Mayo Clinic, with a special interest in the genetics of movement disorders and advanced clinical training in the neurophysiology and botulinum toxin treatment of abnormal movements.

Dr. Goudreau joined the MSUCOM faculty in July 2001, where he continues his scientific and clinical interests in Parkinson's disease and other movement disorders as a tenured associate professor in the Departments of Neurology and Pharmacology-Toxicology. In 2019, he was selected as the Associate Dean for Research in the MSU College of Osteopathic Medicine and co-director of the DO-PhD training program, a combined degree program where students are trained to become physician scientists. He was also appointed as the Director of the MSU Clinical & Translational Science Institute, which facilitates university-wide clinical/translational research infrastructure.

Dr. Goudreau's research is focused on developing symptomatic and neuroprotective therapies for Parkinson's and related neurodegenerative disorders. Dr. Goudreau is board certified in neurology and was elected a fellow of the American Osteopathic Board of Neurology and Psychiatry. He is an active member of the American Academy of Neurology, Movement Disorders Society, Parkinson Study Group and the American Osteopathic Association. Dr. Goudreau was elected as a member of the NBOME Board during its December 2014 Annual Meeting, has formerly served in COMLEX-USA Level 2-CE and Level 1 Coordinator roles, and as chair of the Clinical Decision-making Subcommittee. He is also a member of the COMLEX-USA Level 3 Advisory Committee.